Logo

CEPI Expands its Investment in the Development of Vaccine Against COVID-19

Share this

CEPI Expands its Investment in the Development of Vaccine Against COVID-19

Shots:

  • CEPI to provide $4.4M to Novavax & the University of Oxford for accelerating the development of vaccines against COVID-19. CEPI has invested up to $23.7M in R&D of COVID-19 vaccines
  • Novavax is assessing multiple nanoparticle vaccine candidates to identify the best candidates for clinical studies. CEPI will provide the initial funding to Novavax for the initiation of P-I study- which is expected to be initiated in H1’20
  • The company has developed the vaccine candidates using its recombinant protein nanoparticle technology to generate antigens derived from the coronavirus spike protein and is expected to utilize its Matrix-M adjuvant to enhance the immune response of vaccine candidates

Source 1- Source 2 ­to­ read full press release/ article | Ref: CEPI- GlobeNewswire | Image: CEPI


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions